TrialEuropean heart journal2017

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.

Michael Böhm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.